U
Ursina R. Teitelbaum
Researcher at University of Pennsylvania
Publications - 64
Citations - 2758
Ursina R. Teitelbaum is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 13, co-authored 51 publications receiving 2170 citations. Previous affiliations of Ursina R. Teitelbaum include University of Texas MD Anderson Cancer Center & Hospital of the University of Pennsylvania.
Papers
More filters
Journal ArticleDOI
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
Gregory L. Beatty,Elena G. Chiorean,Matthew P. Fishman,Babak Saboury,Ursina R. Teitelbaum,Weijing Sun,Richard D. Huhn,Wenru Song,Dongguang Li,Leslie L. Sharp,Drew A. Torigian,Peter J. O'Dwyer,Robert H. Vonderheide +12 more
TL;DR: These findings demonstrate a CD40-dependent mechanism for targeting tumor stroma in the treatment of cancer and demonstrate that cancer immune surveillance does not necessarily depend on therapy-induced T cells; rather, it is shown that tumor regression required macrophages but not T cells or gemcitabine.
Journal ArticleDOI
A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma
Gregory L. Beatty,Drew A. Torigian,E. Gabriela Chiorean,Babak Saboury,Abass Alavi,Andrea B. Troxel,Weijing Sun,Ursina R. Teitelbaum,Robert H. Vonderheide,Peter J. O'Dwyer +9 more
TL;DR: CP-870,893 in combination with gemcitabine was well-tolerated and associated with antitumor activity in patients with PDA, and changes in FDG uptake detected on PET/CT imaging provide insight into therapeutic benefit.
Journal ArticleDOI
Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer: A Phase 2 Randomized Clinical Trial.
Thomas B. Karasic,Mark H. O'Hara,Arturo Loaiza-Bonilla,Arturo Loaiza-Bonilla,Kim A. Reiss,Ursina R. Teitelbaum,Erkut Borazanci,Ana De Jesus-Acosta,Colleen Redlinger,Jessica A. Burrell,Daniel A. Laheru,Daniel D. Von Hoff,Ravi K. Amaravadi,Jeffrey A. Drebin,Jeffrey A. Drebin,Peter J. O'Dwyer +15 more
TL;DR: The data do not support the routine use of GA plus HCQ for metastatic pancreatic cancer in the absence of a biomarker, however, improvement seen in the overall response rate with HCQ may indicate a role for HCQ in the locally advanced setting, where tumor response may permit resection.
Journal ArticleDOI
Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma.
Weijing Sun,Davendra Sohal,Daniel G. Haller,K. Mykulowycz,Mark A. Rosen,Michael C. Soulen,Millie Caparro,Ursina R. Teitelbaum,Bruce J. Giantonio,Peter J. O'Dwyer,Abraham Shaked,Rajender Reddy,Kim M. Olthoff +12 more
TL;DR: This phase 2 study was designed to determine the efficacy and toxicity of the combination of bevacizumab, capecitabine, and oxaliplatin in patients with advanced unresectable and untransplantable HCC.
Journal ArticleDOI
Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2.
Kim A. Reiss,Rosemarie Mick,Mark H. O'Hara,Ursina R. Teitelbaum,Thomas B. Karasic,Charles Schneider,Stacy Cowden,Traci Southwell,Janae Romeo,Natallia Izgur,Zain M. Hannan,Rashmi Tondon,Katherine L. Nathanson,Robert H. Vonderheide,Max M. Wattenberg,Gregory L. Beatty,Susan M. Domchek +16 more
TL;DR: PURPOSEOlaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi), is approved as maintenance therapy for patients with advanced pancreatic cancer (PC) and a germline BRCA1 or BRCa2 pathogen as discussed by the authors.